The EuroSCAR study: Cannot agree with the conclusions

Journal of the American Academy of Dermatology

Volumn 59, Issue 5, 2008, Pages 898-899

  Pehr, Kevin ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; PREDNISONE;

CORTICOSTEROID THERAPY; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; IMMUNOTHERAPY; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ADRENAL CORTEX HORMONES; EPIDERMAL NECROLYSIS, TOXIC; FRANCE; GERMANY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; STEVENS-JOHNSON SYNDROME;

EID: 53349156367     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.07.004     Document Type: Letter

References (6)

1. Schneck J., Fagot J.P., Sekula P., Sassolas B., Roujeau J.C., and Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol 58 (2008) 33-40
2. Brown K., Silver G., Halerz M., Walaszek P., Sandroni A., and Gameli R. Toxic epidermal necrolysis: does immunoglobulin make a difference?. J Burn Care Rehabil 25 (2004) 81-88
3. Bachot N., Revuz J., and Roujeau J.C. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 139 (2003) 33-36
4. Prins C., Kerdel F., Padilla R., Hunziker T., Viard I., Mauri D., et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins. Arch Dermatol 139 (2003) 26-32
5. Shortt R., Gomez M., Mittman N., and Cartotto G. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 25 (2004) 246-255
6. Trent J., Kirsner R., Romanelli P., and Kerdel F. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN. Arch Dermatol 139 (2003) 39-43